Sequence: SFSIIHTPILPL
| Experiment Id | EXP002542 |
|---|---|
| Paper | A Multifunctional Lipid-Based Nanodevice for the Highly Specific Codelivery of Sorafenib and Midkine |
| Peptide | SP94 |
| Delivery Success Class | no |
| In Vivo Flag | no |
| Uptake Confirmed | yes |
| Label Confidence | high |
| In Vitro Functional Effect | yes |
| Endosomal Escape Evidence | |
| Peptide Concentration | 5 mol% DSPE-PEG-SP94 (surface) |
| Rna Concentration | 400 nM (typical; also 200 nM when SOR=5 µM) |
| Mixing Ratio | siRNA:drug molar ratio 1:25 (0.4 µM siRNA : 10 µM SOR); siRNA/lipid ~1:500; PEI N/P=0.5 core |
| Formulation Format | Lipid nanoparticles (LNPs); siRNA/PEI core + lipid film hydration; sonication; ultrafiltration |
| Formulation Components | YSK05/EPC/cholesterol/DSPE-PEG-SP94 = 4:3:3:0.5 (molar ratio); siRNA/PEI core (N/P=0.5); SOR co-loaded |
| Size Nm | 150.00 |
| Zeta Mv | -10.50 |
| Model Scope | in_vitro |
| Model Type | in vitro |
| Cell Lines Or Primary Cells | HepG2 (human HCC); Hepa 1-6 (mouse HCC); HeLa; FL83B (normal mouse hepatocytes) |
| Animal Model | |
| Administration Route | |
| Output Type | MK mRNA knockdown EC50 (qRT-PCR) + cytotoxicity readouts |
| Output Value | MK knockdown EC50 7.50 ± 2.50 nM (HepG2) and 10 ± 3.50 nM (Hepa 1-6); IC50 (SOR+MK-siRNA) 5 ± 1.50 µM in HepG2; selective uptake vs FL83B (~27× at 5 mol% SP94) |
| Output Units | |
| Output Notes | Selectivity confirmed by FACS + CLSM. SP94 provides HCC targeting; YSK05 pH-sensitive lipid used to promote endosomal escape; serum compatible and stable in storage. |
| Toxicity Notes | Higher biosafety/selectivity: limited uptake and cytotoxicity in FL83B compared to STR-R8-NPs. |
| Curation Notes |